Skip to main content
. 2023 May 3;14:1188018. doi: 10.3389/fimmu.2023.1188018

Figure 2.

Figure 2

Ex vivo expansion of NHP CE-XTCs and supporting cells. NHP CE-XTCs were prepared as described in Figure 1 and cell counts at each manufacturing phase were determined from SHIV-infected, ART suppressed donors (closed circles, n = 5) and uninfected donors (open circles, n = 2). (A) Cell counts from representative manufacturing time points detailed in Figure 1, including initiation of DC culture (Day -8 DC), CE-XTCs on Day 0 and Day 11 following addition of CE-peptide pulsed, irradiated DC, PHA blasts on Day 4 (thaw day) and Day 11 (after 7 days of expansion), and co-cultured CE-XTC on Day 11 (addition of expanded PHA blasts and GM-K562) and Day 17 (after 6 days of expansion). “CE-XTC + PHA Blasts + GM-K562” includes comparisons of cell numbers from SHIV-infected, ART-suppressed donors at day 11 and 17 when expanded in the absence (-ART) or presence (+ART) of antiretroviral drugs in the culture media. (B) Fold expansion for the CE-XTC, PHA blasts, and CE-XTC/PHA blast/GM-K562 mixed cultures in the absence (-ART) or presence (+ART) during the indicated time interval. C:P:G refers to the final co-culture of CE-XTC, PHA blasts, and GM-K562 feeders. Cells from uninfected donors (animal IDs A17044 and A17045) were only assessed in the absence of ART. In subsequent figures, CE-XTC phenotypic and functional data includes 3 of 5 SHIV-infected, ART-suppressed donors (IDs A17026, A17032, and A17035) but was not available from 2 others (IDs A17023 and A17025).